Cannabis Trademarks Not Stoned by PTO
Client Alert | 1 min read | 05.07.19
In new guidelines issued this past Thursday, May 2, 2019, the United States Patent & Trademark Office clarified the procedure for examining trademarks for cannabis-derived goods, services involving cannabis, and cannabis production. These guidelines explain that the 2018 Farm Bill exempts hemp (defined as cannabis plants and derivatives such as CBD that contain no more than 0.3 percent THC on a dry-weight basis) from the definition of marijuana in the Controlled Substances Act (21 U.S.C. § 801 et seq.)(CSA).
Thus, for applications that identify goods and/or related services encompassing cannabis or CBD, the 2018 Farm Bill potentially removes the CSA as a ground for refusal of registration under the following conditions:
- The goods and/or related services are derived from hemp.
- The identification of goods and/or services specify that the hemp products contain less than 0.3 percent THC.
- The application was filed on or after December 20, 2018, except that for applications filed before December 20, 2018, applicants have the option of amending the filing date and filing basis of the application to overcome the CSA as a ground of refusal.
Despite these guidelines, applicants should be aware that hemp related goods and/or services may still raise lawful-use issues under other laws, including the Federal Food Drug and Cosmetic Act (FDCA).
A link to the guidelines may be accessed here: USPTO Examination Guide 1-19.
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions